The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPeking University People's Hospital

About this trial

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment. Immune reconstitution (IR) is critical for improving HSCT efficacy and quality of life among survivors, yet its dynamic impact on survival and complications like chronic graft-versus-host disease (cGVHD) in CMML is poorly defined. This study aimed to investigate the dynamics of IR following HSCT in patients with CMML and evaluate its impact on post-transplant clinical outcomes.

Eligibility criteria

Qualifiers

Patients with confirmed diagnosis of CMML following HSCT

Patients treated at Peking University People's Hospital since January 1, 2005

Disqualifiers

Any condition that may render follow-up data unreliable, including but not limited to severe psychiatric disorders

Patients deemed ineligible for the study by investigators

Trial design

Treatments tested in this trial

  • immune reconstitution

Treatment groups

300 Participants
are divided into 3 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Peking University People's Hospital

Lead sponsor

The First Hospital of Jilin University

Collaborator

960th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Collaborator